PVLA
Palvella Therapeutics, Inc.
$125.10
-1.02%
2026-10-23
About Palvella Therapeutics, Inc.
Palvella Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel therapies to treat patients serious and rare genetic skin diseases. The company's lead product candidate is QTORIN rapamycin, a novel, 3.9% anhydrous topical gel that is in Phase 3 clinical trial for the treatment of microcystic lymphatic malformations, as well as in Phase 2 clinical trial to treat cutaneous venous malformations. It also develops QTORIN rapamycin for the treatment of angiokeratomas and other mTOR-driven skin diseases; and QTORIN pitavastatin for the treatment of disseminated superficial actinic porokeratosis. The company is based in Wayne, Pennsylvania.
Key Fundamentals
Forward P/E
-18.43
EPS (TTM)
$-4.85
ROE
-46.6%
Profit Margin
0.0%
Debt/Equity
10.44
Price/Book
9.17
Market Cap
$1.99B
Avg Volume (10D)
237K
Recent Breakout Signals
Recent Price Range (60 Days)
60D High
$160.84
60D Low
$118.22
Avg Volume
211K
Latest Close
$125.10
Get breakout alerts for PVLA
Sign up for Breakout Scanner to receive daily notifications when PVLA triggers breakout signals. Build custom AI screeners and backtest strategies.
Create your account7-day free trial, no card needed. Then $20/month.
Palvella Therapeutics, Inc. (PVLA) is listed on the NASDAQ (NASDAQ). Breakout Scanner monitors PVLA daily for breakout patterns including long-term ceiling breakouts, momentum breakouts, and near-breakout watch setups. PVLA operates in the Healthcare sector within the Biotechnology industry. Data is provided for informational purposes only and does not constitute financial advice.